Table 1.

Participant demographics and clinical characteristics

Participant ID	Age, years	Sex	Race	Comorbidities	mRNA SARS-CoV-2 vaccination history	Days of symptoms before infusion	Supplemental oxygen at infusion (L)	Infusion dose
DVX201-001	63	M	White	coronary artery disease, hypertension, obesity, type 2 diabetes	1 dose	10	0	100 × 106
DVX201-002	25	M	White	acute lymphoblastic leukemia (ALL), obesity	none	4	0	100 × 106
DVX201-003	72	M	Asian	hypertension, type 2 diabetes	1 dose	6	0	100 × 106
DVX201-004	42	M	Latino	obesity	2 doses	12	6	300 × 106
DVX201-006	42	M	Asian	none	none	12	3	300 × 106
DVX201-007	36	M	Latino	hypertension, metastatic cholangiocarcinoma, obesity	none	6	5	300 × 106
DVX201-008	45	M	Latino	ALL, hypertension, obesity	none	64	2	900 × 106
DVX201-009a	77	F	White	bronchiectasis, chronic lymphocytic leukemia (CLL)	3 doses	87	0	900 × 106
DVX201-010	77	M	White	hypertension, hyperlipidemia, type 2 diabetes	2 doses	6	0	900 × 106

M, male; F, female.

^aNegative SARS-CoV-2 PCR from nasopharyngeal swab but positive in bronchoalveolar lavage sample.